09/02/2026
RASONQUE™ (daraxonrasib) is approved for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This is now considered the new standard of care for patients with previously treated metastatic pancreatic cancer after clinical trial results in this population showed a doubling of survival compared to chemotherapy as well as improved quality of life for patients.
Visit 🔗 https://pancan.org/news/fda-approves-rasonque-daraxonrasib/ to learn more about RASONQUE™, including what this FDA approval means, the survival benefit for people with pancreatic cancer, potential side effects, insurance coverage and how PanCAN Patient Services can help. 💜